Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH

At Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH in Berlin, a large share of the clinical trial activity focuses on respiratory tract diseases and neoplasms, especially different forms of non-small cell lung cancer and small-cell lung cancer. These studies are designed to test new treatment approaches, improve outcomes after surgery, and evaluate whether combination therapies can better control advanced disease.

• Advanced and metastatic non-small cell lung cancer, including EGFR- and KRAS-driven disease
• Small-cell lung cancer and lung neuroendocrine tumors
• Trials assessing new immunotherapy, targeted therapy, and maintenance strategies
• Studies aiming to improve survival, reduce recurrence, and refine treatment selection

This research area reflects the site’s strong expertise in pulmonology and cancer care, with many trials exploring more effective options for patients with advanced or hard-to-treat lung malignancies.

The site is also active in analytical and therapeutic techniques research centered on molecularly defined lung cancers. These trials focus on specific genetic changes such as EGFR mutations, KRAS G12C, ALK, ROS1, and NTRK alterations, with the goal of matching patients to treatments that are more precisely tailored to their tumor biology.

• EGFR-mutated and EGFR exon 20 insertion lung cancer
• KRAS G12C-positive advanced lung cancer
• Solid tumors with ALK, ROS1, or NTRK rearrangements
• Studies comparing targeted medicines with existing standard treatments

These investigations aim to improve treatment effectiveness while helping clinicians choose the most appropriate therapy for patients with genetically defined cancers.

Another major theme at this Berlin site is the evaluation of immunotherapy alone or in combination with chemotherapy and other agents. The studies cover several lung cancer settings, including newly diagnosed, resected, and metastatic disease, and are designed to strengthen the body’s immune response against cancer while improving disease control.

• Use of immune-based treatments in advanced NSCLC and SCLC
• Combination approaches for patients after surgery or chemoradiotherapy
• Research on maintenance treatment to delay disease progression
• Trials assessing whether combination regimens improve survival and response rates

Overall, this work reflects a strong interest in finding more durable and effective cancer treatments through immuno-oncology.

Beyond cancer, the Klinik für Pneumologie is conducting studies in chronic lung diseases such as idiopathic pulmonary fibrosis and pulmonary hypertension associated with interstitial lung disease. These trials focus on understanding whether new therapies can slow lung function decline, improve symptoms, and support better long-term breathing capacity.

• Idiopathic pulmonary fibrosis and related fibrotic lung conditions
• Pulmonary hypertension associated with interstitial lung disease
• Studies evaluating symptom relief and preservation of lung function
• Research aimed at improving quality of life in progressive lung disease

This area highlights the site’s role in advancing care for patients with serious non-malignant respiratory disorders.

The trial portfolio also includes work on bacterial infections and long-standing airway conditions, especially nontuberculous mycobacterial lung infection, chronic pulmonary aspergillosis, and bronchiectasis. These studies are intended to improve symptom control, reduce exacerbations, and evaluate whether new treatment strategies can better manage difficult-to-treat lung infections and airway damage.

• Nontuberculous mycobacterial lung infection
• Chronic pulmonary aspergillosis
• Bronchiectasis with recurrent pulmonary exacerbations
• Trials focused on treatment effectiveness and respiratory symptom improvement

These studies add an important infectious-disease and chronic care dimension to the site’s broader pulmonary research program.

Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH also participates in research on less common respiratory conditions, including severe alpha-1 antitrypsin deficiency and pulmonary arterial hypertension. The purpose of these trials is to assess safety, tolerability, and potential benefit of emerging therapies that may offer new options for patients with limited current choices.

• Severe alpha-1 antitrypsin deficiency
• Pulmonary arterial hypertension
• Studies evaluating safety and long-term treatment use
• Research aimed at expanding options for rare and chronic lung conditions

These projects show a broad commitment to pulmonary medicine, extending beyond cancer into rare and complex breathing disorders.